HALO
NASDAQ · Biotechnology
Halozyme Therapeutics Inc
$62.04
-0.82 (-1.30%)
Financial Highlights (FY 2026)
Revenue
811.57M
Net Income
354.97M
Gross Margin
84.3%
Profit Margin
43.7%
Rev Growth
+31.8%
D/E Ratio
4.14
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.3% | 84.3% | 67.3% | 67.3% |
| Operating Margin | 54.3% | 48.9% | -6.4% | -7.2% |
| Profit Margin | 43.7% | 41.6% | -5.8% | -7.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 811.57M | 615.67M | 1.30B | 1.05B |
| Gross Profit | 684.15M | 519.01M | 873.05M | 707.65M |
| Operating Income | 440.84M | 300.99M | -82,975,143 | -75,519,990 |
| Net Income | 354.97M | 242.36M | -74,995,325 | -75,300,768 |
| Gross Margin | 84.3% | 84.3% | 67.3% | 67.3% |
| Operating Margin | 54.3% | 48.9% | -6.4% | -7.2% |
| Profit Margin | 43.7% | 41.6% | -5.8% | -7.2% |
| Rev Growth | +31.8% | +31.8% | +13.4% | +1.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.38B | 3.38B | 2.05B | 2.54B |
| Total Equity | 817.64M | 817.64M | 5.54B | 5.77B |
| D/E Ratio | 4.14 | 4.14 | 0.37 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 497.60M | 358.61M | -91,476,031 | -72,949,593 |
| Free Cash Flow | — | — | -86,399,966 | -67,262,012 |